These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23846936)

  • 1. Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
    Sarris EG; Syrigos KN; Saif MW
    JOP; 2013 Jul; 14(4):395-400. PubMed ID: 23846936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    Oberstein PE; Saif MW
    JOP; 2011 Mar; 12(2):96-100. PubMed ID: 21386629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
    Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
    J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].
    Krempien R; Muenter MW; Huber PE; Nill S; Friess H; Timke C; Didinger B; Buechler P; Heeger S; Herfarth KK; Abdollahi A; Buchler MW; Debus J
    BMC Cancer; 2005 Oct; 5():131. PubMed ID: 16219105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
    Philip PA; Benedetti J; Corless CL; Wong R; O'Reilly EM; Flynn PJ; Rowland KM; Atkins JN; Mirtsching BC; Rivkin SE; Khorana AA; Goldman B; Fenoglio-Preiser CM; Abbruzzese JL; Blanke CD
    J Clin Oncol; 2010 Aug; 28(22):3605-10. PubMed ID: 20606093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.
    Su D; Jiao SC; Wang LJ; Shi WW; Long YY; Li J; Bai L
    Tumour Biol; 2014 Mar; 35(3):2313-8. PubMed ID: 24142531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
    Kim EJ; Sahai V; Abel EV; Griffith KA; Greenson JK; Takebe N; Khan GN; Blau JL; Craig R; Balis UG; Zalupski MM; Simeone DM
    Clin Cancer Res; 2014 Dec; 20(23):5937-5945. PubMed ID: 25278454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
    Morgan MA; Parsels LA; Kollar LE; Normolle DP; Maybaum J; Lawrence TS
    Clin Cancer Res; 2008 Aug; 14(16):5142-9. PubMed ID: 18698032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.
    De Jesus-Acosta A; Sugar EA; O'Dwyer PJ; Ramanathan RK; Von Hoff DD; Rasheed Z; Zheng L; Begum A; Anders R; Maitra A; McAllister F; Rajeshkumar NV; Yabuuchi S; de Wilde RF; Batukbhai B; Sahin I; Laheru DA
    Br J Cancer; 2020 Feb; 122(4):498-505. PubMed ID: 31857726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
    Burris H; Rocha-Lima C
    Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.
    Bharthuar A; Pearce L; Litwin A; LeVea C; Kuvshinoff B; Iyer R
    JOP; 2009 Sep; 10(5):523-7. PubMed ID: 19734629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
    Casneuf VF; Demetter P; Boterberg T; Delrue L; Peeters M; Van Damme N
    Oncol Rep; 2009 Jul; 22(1):105-13. PubMed ID: 19513511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
    Okusaka T; Ikeda M; Fukutomi A; Kobayashi Y; Shibayama K; Takubo T; Gansert J
    Jpn J Clin Oncol; 2014 May; 44(5):442-7. PubMed ID: 24782485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2012 Jul; 13(4):345-8. PubMed ID: 22797386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Her signaling in pancreatic cancer.
    Burtness B
    Expert Opin Biol Ther; 2007 Jun; 7(6):823-9. PubMed ID: 17555368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
    Awasthi N; Schwarz MA; Schwarz RE
    HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
    Sloss CM; Wang F; Liu R; Xia L; Houston M; Ljungman D; Palladino MA; Cusack JC
    Clin Cancer Res; 2008 Aug; 14(16):5116-23. PubMed ID: 18698029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
    Saif MW
    JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.